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ABSTRACT The use of synbiotics as health promoters is still poorly defined, and human intervention studies are scarce.
This study was designed to evaluate the effects of a commercialized synbiotic product containing Lactobacillus acidophilus
La5, Bifidobacterium animalis ssp. lactis Bb-12, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus paracasei ssp.
paracasei, Streptococcus thermophilus, and fructooligosaccharides on the self-reported gastrointestinal well-being and the
immunoinflammatory status of healthy human subjects. In this randomized, double-blind, placebo-controlled study, 20 women
and 16 men (25–45 years old) received either three tablets per day of the synbiotic product (2.4109 colony-forming
units=day) or placebo during 6 weeks. Gastrointestinal symptoms and bowel habits were evaluated through a self-administered
questionnaire. In those subjects suffering from any kind of digestive disturbance (mild dyspepsia, flatulence, postprandial
bloating, constipation, etc.), improvements in symptoms after product consumption were also evaluated. Blood lymphocyte
subsets, phagocytic activity, serum C-reactive protein, ceruloplasmin, and adhesion molecules concentrations were analyzed
prior and after treatment. A significant improvement in overall self-reported gastrointestinal symptoms and bowel habit was
found in the synbiotic group. A marginal effect of treatment (analysis of variance P¼ .050) was observed with L-selectin,
which showed a significant decrease in the synbiotic group (P¼ .019). In addition, basal L-selectin levels correlated with final
intercellular adhesion molecule (ICAM)-1 levels (r¼ 0.468; P¼ .050), and basal ICAM-1 levels tended to correlate nega-
tively with final L-selectin concentration (r¼ –0.457; P¼ .056). None of these correlations was found in the placebo group.
The rest of the immunological parameters studied were not modified by the intervention. In conclusion, consumption of the
synbiotic product improves self-perceived bowel habits and might facilitate a better profile of adhesion molecules in healthy
adults.
KEY WORDS:  adhesion molecules  bowel habits  gastrointestinal symptoms  immunomodulation  inflammatory
proteins  lymphocyte subsets  probiotic bacteria
INTRODUCTION
Synbiotic preparations containing a combination ofprobiotics and fermentable fiber (prebiotic) are consid-
ered a healthy dietary supplement in the restoration and
maintenance of colonic flora. Probiotics are defined as
live microorganisms that when administered in adequate
amounts confer a health benefit on the host.1 Microorgan-
isms that are principally used as probiotics include various
species of lactobacilli or bifidobacteria, used individually or
in combination, whereas the most used prebiotic fibers in-
clude inulin and fructooligosaccharides (FOS). Many human
studies confirm that FOS have a bifidogenic effect on human
colonic endogenous flora.2 Moreover, because the prebiotic
fibers are preferential substrates for bifidobacteria, adding
the prebiotic molecules to the probiotics would increase
the survival rate of the bifidobacteria during intestinal transit
and thus their effect on the colon.3,4 However, because
probiotics do not permanently colonize the intestine, they
must be taken in sufficient quantities to maintain adequate
amounts in the colon. The principal purported health-
promoting effects of probiotics are the enhancement of
mucosal immune defenses, with an adjuvant effect, in-
creased polymeric immunoglobulin A production, and cy-
tokine stimulus,5–7 resulting in modulation of systemic
immunity, which adds to the general mechanisms conferring
a protective effect against pathologic microbial colonization
and translocation.8 The major effects claimed for the pre-
biotic components in functional foods include improved
bowel function, increased mineral absorption, and a reduced
risk of cardiovascular disease associated with dyslipidemia,
insulin resistance, obesity, and possibly type 2 diabetes and
of colon cancer.9
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The use of synbiotics as health promoters is still poorly
defined, and studies with combinations of pro- and prebi-
otics are still scarce. The effects of synbiotic therapies on
intestinal function of different types of critically ill patients
have been investigated in a few studies including infants10
and adults.11,12 Synbiotics have also proved useful in short
bowel syndrome,13,14 ulcerative colitis,15–17 and acute pan-
creatitis,18 although some of these are only preliminary
studies without a control group.
A substantial amount of work has been published with the
probiotic strains Lactobacillus acidophilus La5 and Bifido-
bacterium animalis ssp. lactis Bb12 present in the synbiotic
product used in our study. The combination of the strains
L. acidophilus La5, B. animalis ssp. lactis Bb12, and yogurt
culture starters with or without prebiotics has been assessed
in several conditions, such as Helicobacter pylori infec-
tion19 and critically ill patients admitted into the intensive
care unit.11 The results suggest that the supplements provide
a favorable alteration of the microbial composition of the
upper gastrointestinal tract.
Based on the lack of studies assessing the usefulness
of synbiotics in healthy individuals, the main objective of
this study was to evaluate the effects of a synbiotic product
containing five lactic acid bacterial strains and FOS on self-
perceived gastrointestinal well-being and immunoinflam-
matory status of healthy adults. Second, in those subjects
suffering from any kind of digestive disturbance such as
mild dyspepsia, flatulence, postprandial bloating, constipa-
tion, etc., improvements in symptoms after product con-
sumption were also evaluated.
MATERIALS AND METHODS
Study population
Healthy adults (n¼ 42) 25–45 years old were recruited in
the technological park of Valencia, Spain, for a pilot study
with the synbiotic product. The sample size was chosen in
order to provide enough statistical power for immune pa-
rameter changes on the basis of the data reviewed in the
literature.20–23 The exclusion criteria were the following: to
be a vegetarian or to be on a diet, to suffer from any diag-
nosed gastrointestinal disease, chronic diseases such as
diabetes and=or dyslipidemia, have had intestinal resections,
or receiving chronic pharmacological treatment or acute
antibiotic treatment 2 weeks prior to the intervention. Tak-
ing these criteria into account, 37 volunteers were finally
included in this study who were judged to be in good health
on the basis of physical examination and medical history.
The volunteers provided written informed consent prior to
the start of the study, and it was conducted in accordance
with the ethical rules of the Helsinki Declaration (52nd
World Medical Association General Assembly, held in
Edinburgh, United Kingdom, in October 2000), and the EEC
Good Clinical Practice guidelines (document 111=3976=88
in July 1990). One volunteer did not complete the study,
thus leaving 18 subjects in each study group with a fe-
male:male ratio of 10:8 in both groups. The study was ap-
proved by the Ethics Committee of Virgen de los Lirios
Hospital, Alcoy, Spain.
Study design
In this double-blind study, the subjects were randomly
allocated to one of two groups matched by sex and age and
received either three placebo capsules per day (containing
sucrose, talcum powder, and stearic acid magnesium salt) or
three tablets per day of the synbiotic product (SYMBYO,
Laboratorios Phergal S.A., Torrejon de Ardoz, Spain). Each
tablet contained a combination of five bacterial strains in
approximately equal numbers (L. acidophilus La5, B. ani-
malis ssp. lactis Bb-12, Lactobacillus delbrueckii ssp. bul-
garicus, Streptococcus thermophilus, and Lactobacillus
paracasei ssp. paracasei [Probio-Tec, Chr. Hansen, Hør-
sholm, Denmark]) and FOS. The tablet was developed to be
taken with thorough chewing, whereas the polysaccharide
matrix allowed the formation of a protective gel in acid pH
that improved survival of the bacteria until the intestine was
reached. The consumption of three tablets per day accounted
for a total daily consumption of 2.4109 colony-forming
units and 1.4 g of FOS. The subjects were advised to con-
sume the tablets after their three main meals. They were also
asked to continue with their normal diet, but they were not
allowed to consume any other fermented dairy products,
prebiotic, probiotic, or synbiotic supplement, or fiber-
enriched products during the study and 2 weeks prior to the
intervention. They were only allowed to eat non-dairy fer-
mented products, such as dry=cured meat, beer, or wine, if
that was their previous habit. The intervention was con-
ducted for 6 weeks. Compliance with the product or placebo
consumption was good as assessed in the final questionnaire.
In the early morning 12-hour fasting venous blood sam-
ples were collected at the start of the study (T1) and 6 weeks
later at the end of the examination period (T2). Before the
specimens were obtained a questionnaire was administered
in order to exclude alterations of immune parameters due to
any current illness, such as allergy or infection. Blood sam-
ples were always analyzed for hematological and immuno-
logical variables within 4–5 hours after they were obtained.
Basic anthropometric measurements (body weight, height,
and waist circumference) were performed on the volunteers
at the same visits.
Lifestyle, dietary habits, and self-reported gastrointesti-
nal well-being were assessed at baseline through a ques-
tionnaire including questions on food intake frequency,
physical activity, smoking habit, gastrointestinal symptoms
(constipation, diarrhea, flatulence, postprandial bloating,
lactose intolerance, and dyspepsia), and respiratory infec-
tions, all relative to the previous 2 months. Each of these
symptoms was verbally explained to all subjects in order to
standardize the evaluation criteria. These symptoms were
explained as a simplification of the Rome II diagnostic
criteria as follows: dyspepsia as pain or discomfort centered
in the upper abdomen; postprandial bloating as a feeling of
abdominal fullness or bloating after eating; constipation as
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two or more of the following—frequency of stools lower
than three times a week, stools that are hard and lumpy,
necessity to strain during defecation, and necessity to use
laxatives; diarrhea as a high frequency of loose or watery
stools (more than three-fourths of the time); and alternating
diarrhea=constipation, as both conditions tend to appear in
alternation and=or combined with periods of normal func-
tion. Moreover, lactose intolerance was explained as the
feeling of stomach sickness after eating foods with lactose
in them, accompanied or not by other symptoms such as
bloating, gas, or diarrhea. Finally, flatulence was described
as an excessive passage and expulsion of gas through the
intestine that can be bothersome. In the end-point ques-
tionnaire the subjects were asked to evaluate subjectively,
through one closed question (improvement: yes or no) any
alleviation in previously reported symptoms and also any
improvement in their bowel habits regarded as regularity of
defecations over the 6-week intervention period. The num-
ber of stools per day at the end of the treatment was also
measured as a recall estimate in a time frame covering the
last 2 weeks. The volunteers filled out a 24-hour dietary
recall questionnaire administered in three different occa-
sions: at the start, midpoint, and end of the study, with the
last one carried out on a holiday.
Analysis of hematological and immunological parameters
Hematology was analyzed in whole blood samples col-
lected into EDTA using an automated analyzer (Sysmex XE-
2100, Roche Diagnostics, Basel, Switzerland), including red
blood cell counts, hemoglobin, hematocrit, red blood cell
corpuscular indices, white blood cell counts, differential,
and platelets. Lymphocyte subsets were analyzed by flow
cytometry (FACScan, BD, Sunnyvale, CA, USA). Whole
blood was incubated with monoclonal antibodies for CD3
(mature T cells), CD4 (helper cells), CD8 (cytotoxic=
suppressor cells), and CD56þCD16 (natural killer cells)
following the manufacturer’s instructions (BD Biosciences,
San Jose, CA, USA). The double staining procedure
(CD3=CD4, CD3=CD8, and CD3=CD56þCD16) was used.
Phagocyte function was quantitatively assessed using a
Phagotest kit (BD Biosciences) and flow cytometry. In-
flammatory proteins such as highly sensitive C-reactive
protein and ceruloplasmin were measured in serum by
immunoturbidimetry (model AU2700 biochemistry analyzer,
Olympus, Rungis, France). The serum adhesion molecules—
soluble intercellular adhesion molecule (ICAM)-1, soluble
vascular cell adhesion molecule (VCAM)-1, and soluble L-
selectin—were analyzed with commercial enzyme-linked
immunosorbent assay kits (Diaclone, Besanc¸on, France). The
sensitivities of these kits were less than 0.1 ng=mL for soluble
ICAM-1, less than 0.6 ng=mL for soluble VCAM-1, and less
than 1 ng=mL for soluble L-selectin.
Statistical analysis
All data are expressed as mean and SD values. The sta-
tistical analysis of symptoms and its self-reported improve-
ment was assessed by means of contingency tables and the
Monte–Carlo exact test (two-tailed P value was consigned).
The effect of the synbiotic on hematological and immuno-
logical variables was assessed by one-way analysis of var-
iance repeated-measures. When the analysis of variance test
was significant, pairwise comparisons by Student’s t test
(paired) were performed to further analyze the changes in-
duced by the intervention within each group. A two-way
analysis of variance repeated-measures was also performed
in order to check any possible sex by group interaction.
Between-group differences were analyzed both prior to and
after the intervention by Student’s t test. Values of P< .05
were considered significant. All statistical analyses were
performed using SPSS version 13.0 software (SPSS, Inc.,
Chicago, IL, USA).
RESULTS
No differences were observed in height (control group,
166.3 7.1 cm; synbiotic group, 167.7 9.6 cm; P¼ .620),
weight (control group, 64.25 10.98 kg; synbiotic group,
66.66 10.99 kg; P¼ .514), or body mass index (control
group, 23.06 2.32 kg=m2; synbiotic group, 23.74 2.19
kg=m2; P¼ .493). In addition, no significant sex by group
interaction in these anthropometric variables was found.
Regarding evaluation parameters, no differences were ob-
served between the groups in the basal values of any of them
(frequency of each gastrointestinal symptom or respiratory
infections, P between .338 and 1.0; hematological variables,
P between .117 and .881; lymphocyte subsets, P between
.113 and .881; phagocytic capacity, P¼ .908; inflammatory
proteins, P¼ .227 for C-reactive protein and P¼ .958 for
ceruloplasmin; and adhesion molecules, P between .204
and .487), which means that the placebo and the synbiotic
groups are comparable in all relevant parameters prior to the
intervention.
Table 1 presents the frequency of several gastrointestinal
symptoms and infections in each group as obtained from the
data reported by the subjects in the questionnaire previous to
the treatment and also the changes reported in these symp-
toms following treatment. A total of 17 subjects reported
suffering from gastrointestinal symptoms or frequent re-
spiratory infections: eight in the placebo group and nine in
the synbiotic group. The main difference between groups
was found for the improvement in bowel habits, which was
reported significantly more in the synbiotic group than in the
placebo group (eight out of 18 in the synbiotic group and
none in the placebo group). The number of stools per day
showed a nonsignificant trend towards higher values in the
synbiotic group (P¼ .082); however, because the number of
stools per day was not assessed prior to the intervention we
cannot rule out that the trends already existed basally. Re-
garding the sum of symptoms, the cumulative self-reported
improvement in any symptom was significantly more fre-
quent in the synbiotic than in the placebo group (P< .05).
Diet seems not to be accountable for these effects because
no differences were observed in the mean energy and
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macronutrient and fiber intakes between the synbiotic and
the placebo groups (Table 2), and no differences were found
either between the three different 24-hour recall question-
naires performed in weeks 0, 3, and 6. During the study
period six subjects took occasionally some kind of cold
symptom relievers or pain relievers (such as ibuprofen or
acetylsalicylic acid); however, three of them belonged to
each study group.
Tables 3 and 4 show the results obtained for the immu-
nological parameters measured. No significant interaction
of time by group was observed in any hematological (data
not shown) or immunological parameter except the serum
concentration of L-selectin, which showed a significant
decrease in the synbiotic group (P¼ .019), whereas no dif-
ferences were observed between the basal and final mea-
surements in the placebo group (P¼ .783). Regarding,
however, the comparison of the final values observed in
both groups, no differences were found in L-selectin. On
the other hand, a significantly higher CD3þCD4þ percent-
age was observed in the synbiotic group than in the pla-
cebo group (P¼ .003), but this was not reflected in the
CD3þCD4þ counts, which were similar between groups
(P¼ .180).
All adhesion molecules showed significant correlations
between basal and final values for both all subjects to-
gether or split by treatment groups. Moreover, ICAM-1 and
VCAM-1 showed correlation with each other. When cor-
relations were analyzed in the two groups defined by treat-
ment, it was observed that in the synbiotic group the basal
L-selectin level correlated with final ICAM-1 level
(r¼ 0.468; P¼ .050) and the basal ICAM-1 level correlated
negatively with final L-selectin concentration (r¼ –0.457;
Table 1. Basal Frequency and Postintervention Improvement in the Gastrointestinal Symptoms
and Respiratory Infections in Healthy Subjects Receiving Placebo or Synbiotic Supplementation
Presence of symptom
Monte–Carlo
exact test P
Self-reported improvement
Monte–Carlo
exact test PPlacebo (n¼ 18) Synbiotic (n¼ 18) Placebo Synbiotic
Dyspepsia 2=18 2=18 1.0 0=2 0=2 —
Postprandial bloating 1=18 3=18 .603 0=1 1=3 1.0
Lactose intolerance 0=18 1=18 1.0 — 1=1 —
Flatulence 3=18 4=18 1.0 1=3 4=4 .143
Chronic diarrhea 0=18 0=18 — — — —
Constipation 1=18 4=18 .338 0=1 3=4 .400
Alternating diarrhea=constipation 2=18 0=18 .486 0=2 — —
Frequent respiratory infections 2=18 2=18 1.0 0=2 1=2 1.0
Sum of symptoms [0, 1, 2]a [0, 1, 2]a .565 [0, 1]b [0, 1]b <.05
(n¼ 9, 7, 2) (n¼ 8, 5, 5) (n¼ 8, 1) (n¼ 3, 7)
Bowel habits — — 0=18 8=18 .003
Placebo Synbiotic P
Number of stools=day after treatment [0, 1, 2, 3]c [0, 1, 2, 3]c .082
(n¼ 3, 15, 0, 0) (n¼ 1, 12, 4, 1)
aThe coding used is 0¼ no symptoms, 1¼ one symptom, and 2¼ two or more symptoms.
bThe coding used is 0¼ no symptom improved and 1¼ one or more symptoms improved.
cThe coding used is 0¼ no stools per day, 1¼ one stool per day, 2¼ two stools per day, amd 3¼more than two stools per day.
Table 2. Energy and Macronutrient Intakes in Healthy Subjects Receiving Placebo or Synbiotic Supplementation
Placebo Synbiotic P
Energy (Kcal) 2,122 420 1,935 274 .127
Total protein (%) 17.95 4.28 18.48 4.39 .720
Vegetable protein (%) 4.50 1.20 4.89 0.86 .284
Animal protein (%) 13.44 4.79 13.59 4.80 .929
Total fat (%) 43.56 5.49 41.87 4.86 .340
SFA (%) 14.65 3.10 13.77 3.01 .400
MUFA (%) 17.48 3.83 16.94 33.58 .665
PUFA (%) 7.99 2.58 8.05 2.40 .943
Total carbohydrates (%) 36.87 6.75 38.26 7.20 .561
Soluble sugars (%) 17.42 4.36 17.68 6.01 .887
Starch (%) 19.50 4.62 20.58 6.80 .603
Fiber (g) 17.29 4.62 16.33 5.93 .597
Data are meanSD values. Data were obtained by pooling the results of the three 24-hour recall questionnaires filled in during the study (basal, 3 weeks, and 6
weeks). All macronutrient intakes (except fiber) are expressed as a percentage of total energy intake.
MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
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P¼ .056). In contrast, no significant correlations were ob-
served between L-selectin and ICAM-1 in the placebo
group. The correlations found in the synbiotic group suggest
that the decrease in L-selectin seems to occur in those pa-
tients who previously showed the highest levels of ICAM-1.
In fact, if the subjects in the synbiotic group are considered
in two groups according to those showing higher or lower
values than 455 ng=mL in T1 (n¼ 9 in each group), the
relative change in the group with higher values is a decrease
of the 17% from basal values, whereas in the group with
lower ICAM-1 values the relative change in L-selectin is a
decrease of only 3%. The difference between these relative
changes, however, does not reach statistical significance
(P¼ .092).
DISCUSSION
Debate is currently open in the scientific community
concerning the benefits of probiotics and prebiotics for
adults with normal, healthy intestinal ecosystems; however,
because the microbiota has such an important role in the
intestinal metabolism and natural defense of the host, a great
value has been conferred on probiotic bacteria able to
counteract environmental factors (such as antibiotic thera-
py), capable of improving the barrier function of the mucosa
and the resistance to the invasion and proliferation of path-
ogenic species and of promoting the gut-associated lym-
phoid tissue. This study showed that a 6-week intervention
in healthy adults with a synbiotic product containing L.
acidophilus La5, B. lactis Bb12, L. delbrueckii ssp. bul-
garicus, S. thermophilus, L. paracasei ssp. paracasei, and
FOS improves the self-reported bowel habits and gastroin-
testinal symptoms. The importance of these findings is
limited by the intrinsic value of self-assessment, which in-
volves some degree of subjective evaluation, with a possible
recall bias. Despite this, self-assessment with diary record-
ing of bowel movements is a tool that has been reported in
the literature.24 Another limitation of this evaluation is that
the severity of the symptoms prior to the intervention was
not assessed.
Regarding blood parameters, the serum concentration of
L-selectin was modified by administration of the synbiotic.
Both B. lactis Bb 12 and L. acidophilus La5 have shown
adhesion capacity to intestinal mucus from healthy children
(31% and 4%, respectively), and it is believed that the ad-
herence of probiotic strains to the mucosa is related to their
Table 3. Lymphocyte Subsets in Healthy Subjects Receiving Placebo or Synbiotic Supplementation
Placebo Synbiotic
T1 T2 T1 T2 ANOVA P
Helper T cells (CD3þCD4þ)
% 39.42 7.29 40.85 5.91 44.00 9.18 47.50 6.14# .418
Cells=mL 830 356 873 367 1,015 437 1,087 366 .744
Cytotoxic T cells (CD3þCD8þ)
% 27.11 7.49 27.31 6.54 25.19 6.02 25.42 5.19 .953
Cells=mL 564 214 585 258 576 282 584 212 .995
NK cells CD3–(CD56þ 16)þ
% 14.27 7.62 13.08 6.55 11.69 5.08 10.59 4.12 .804
Cells=mL 287 160 278 187 253 126 233 93 .767
CD4=CD8 (cells=mL) 1.59 0.58 1.58 0.45 1.85 0.60 1.96 0.52 .500
Data are meanSD values. No significant differences were found between treatment groups in T1.
#Significant differences between treatment groups after the intervention (T2) by Student’s t test: P< .01.
ANOVA, analysis of variance; NK, natural killer; T1, prior to treatment; T2, after 6 weeks of synbiotic consumption.
Table 4. Phagocytic Capacity and Inflammatory Proteins in Healthy Subjects Receiving Placebo or Synbiotic Supplementation
Placebo Synbiotic
T1 T2 T1 T2 ANOVA P
Phagocytic capacity (%) 93.30 0.89 91.33 2.38 93.37 2.10 90.84 3.28 .602
CRP (mg=L) 0.88 0.72 0.90 0.68 1.38 1.44 1.24 1.28 .705
Ceruloplasmin (mg=dL) 33.8 9.4 30.5 4.0 33.4 10.1 33.9 10.7 .219
sICAM-1 (ng=mL) 469 85 433 82 434 78 406 50 .674
sVCAM-1 (ng=mL) 615 212 575 198 545 126 521 148 .732
sL-selectin (ng=mL) 2,586 555 2,560 626 2,724 600 2,389 420* .050
Data are meanSD values. No significant differences were found between treatment groups in T1 and T2.
*Significant differences between T1 and T2 values within groups by paired t test: P< .05.
CRP, C-reactive protein; sICAM-1, soluble intercellular adhesion molecule-1; sL-selectin, soluble L-selectin; sVCAM-1, vascular cell adhesion molecule-1.
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immunomodulatory properties,25 which might help explain
the effect on serum L-selectin levels in the current study. It
is also important to underline that the synbiotic consumption
in the conditions of this study did not bring any negative side
effects to the volunteers.
The self-reported enhancement in bowel habits of the
participating subjects is in agreement with previous re-
ports on the effects of synbiotic administration on intesti-
nal function of patients with gastrointestinal disease10,14 as well
as in healthy subjects.26,27 This effect has been attributed to the
role of short-chain fatty acids, such as acetate, propionate,
and butyrate (end products of bacteria metabolism), in the
large bowel. Although these fatty acids have been studied
for their role in intestinal motility,28,29 considerably more
studies have focused on butyrate for its role in nourishing
the colonic mucosa and in the prevention of colon cancer30 and
also for its influence on cytokine production by immune cells,
which has produced so far controversial results.31,32
L-selectin levels are measured in serum or plasma as a
marker of the L-selectin levels in lymphocytes and neutro-
phils. One early phase of atherosclerosis involves the re-
cruitment of inflammatory cells from the circulation and
their transendothelial migration. Selectins (P, E, and L) and
their ligands are involved in the rolling and tethering of
leukocytes on the vascular wall, whereas ICAMs and
VCAMs, as well as some of the integrins, induce firm ad-
hesion of inflammatory cells at the vascular surface.33 Ex-
pression of VCAM-1, ICAM-1, and L-selectin has been
consistently observed in atherosclerotic plaques. Thus, the
decrease in L-selectin levels in the subjects consuming the
synbiotic might lessen the magnitude of ongoing inflam-
matory processes. However, it should be considered that the
effect of treatment was only marginally significant, and no
differences were found in the final values of L-selectin be-
tween the synbiotic and the placebo groups, which reduces
the importance of the pre-to-post within-group finding. On
the other hand, it is worth noting that the subjects’ L-selectin
values were always within the normal range, and clearer
benefits might occur in subjects with cardiovascular risk
factors. The correlations observed seem to point out a reg-
ulatory mechanism affecting L-selectin and ICAM-1 levels
that is favored by the synbiotic. This is relevant because
there is accumulating evidence from prospective studies
suggesting that elevated circulating levels of soluble ICAM-
1 might predict cardiovascular events in initially healthy
people.34–36 In this regard, probiotic bacteria belonging to
the species L. caseii have been shown to reduce leukocyte
trafficking to an inflamed segment of bowel, because of
decreased ICAM-1 expression on vascular cells in an ex-
perimental model of colitis.37 The effect of probiotics on
adhesion molecules suggests an interaction of bacterial
components present in the synbiotic with the gastrointestinal
resident cells, such as epithelial and immune cells (macro-
phages, dendritic cells, and lymphocytes). Commensal
bacteria have been shown in vivo to interact with intestinal
epithelial cells and to be internalized through specialized
cells, allowing the interaction with underlying immune tis-
sues and the regulation of local immune responses involving
modulation of cytokine secretion and receptor expression
on the cell surface.38
This is a small study regarding the number of subjects
included, which might have been a limitation in observing a
more significant effect on L-selectin. This is in fact a pilot
study that mainly serves to pinpoint possible health ef-
fects of this synbiotic, which are worth looking at in larger,
hypothesis-driven studies, both in healthy subjects and in
patients with cardiovascular disease.
In conclusion, this study shows that daily intake of the
synbiotic supplement has beneficial effects on the self-
perceived bowel habits of healthy subjects and might de-
crease the serum levels of L-selectin, possibly leading to a
more beneficial profile of adhesion molecules regarding the
prevention of atherosclerosis and cardiovascular disease.
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